Clinical Trial Update: Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets [Phase 3]

View source ↗

Summary

Phase III trial assessing the long-term efficacy, carry-over effect, and safety of a 300 IR sublingual immunotherapy tablet for allergy; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• 300 IR Sublingual Immunotherapy Tablet

Snippet

Sponsor: Stallergenes Greer | Conditions: Allergy | Phase 3 | Status: COMPLETED | Results posted: 2016-05-25